Markers for Chronic Obstructive Pulmonary Disease (COPD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2001-07-01

Study Completion Date

2002-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

NCT00655694

Pulmonary Disease, Chronic Obstructive

WITHDRAWN

Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study

NCT01780298

COPD

COMPLETED

The MRC/ABPI COPD Cohort v1.7

NCT01620645

COPD

UNKNOWN

Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study

NCT02076061

Chronic Obstructive Pulmonary Disease Cardiovascular Disease Lung Cancer

COMPLETED

Phenotypes of COPD

NCT03432026

Chronic Obstructive Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Non-smokers Current Smokers COPD Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spirometry

Intervention Type PROCEDURE

Exhaled Nitric Oxide and Carbon Monoxide

Intervention Type PROCEDURE

Exhaled Breath Condensate

Intervention Type PROCEDURE

Induced Sputum

Intervention Type PROCEDURE

CT Scan

Intervention Type PROCEDURE

Blood test

Intervention Type PROCEDURE

St Georges Questionnaire

Intervention Type PROCEDURE

Bodypletysmography

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy non-smokers

* FEV1 \>80% predicted
* FEV1 reversibility of \<10% after inhaled (beta2-agonists

Current smokers

* FEV1 no less than 80% predicted
* FEV1 reversibility of \<10% after inhaled (beta2-agonists
* Smoking history of \> 10 pack-years

Moderate COPD

* FEV1 40-59% predicted
* FEV1 reversibility of \<10% after inhaled (beta2-agonists
* Smoking history of \> 10 pack-years\*\*

Severe COPD

* FEV1 \<40% predicted
* FEV1 reversibility of \<10% after inhaled (beta2-agonists
* Smoking history of \> 10 pack-years

Exclusion Criteria

* FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
* Asthma
* unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes